Finance

Cancer company reports Q2 revenues of $212,000, down from same time last year

Published in Cancer Weekly, September 7th, 2004

Dendreon Corp. (DNDN) reported results for the quarter ended June 30, 2004.

Revenues for the second quarter of 2004 were $212,000 compared to $1.8 million for the quarter ended June 30, 2003.

The decrease in revenue for the quarter ended June 30, 2004 was attributable to the termination of Dendreon's collaboration with Kirin Brewery Co., Ltd., in November 2003. Revenues for the six months ended June 30, 2004 were $4.9 million compared to $3.6 million for the six months ended June 30, 2003. Revenues in the six months ended June 30, 2004 were primarily from Dendreon's license agreement with Nuvelo, Inc., for Dendreon's novel anticoagulant, recombinant...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-09-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry